Our study indicated that there was no significant change in NFκB activity in both lymphoma cell lines with CYLD knockout (OCI-Ly10 and HBL-1) after BTK inhibitor treatment, suggesting that BTKis down-regulated NFκB activity is dependent on the CYLD pathway. The gene discussed is NFKB1; the disease is lymphoma.